Design and Application of Nuclear and Molecular Theragnostic Probes
Abstract With growing propensity towards personalised medication, the application and impact of molecular theragnostic (or, theranostic) is expected to increase dramatically. Molecular theragnostic is the combination of diagnostics and therapeutics in single targeted molecule. If successful, molecular theragnostic will determine the treatment strategy and therapeutic outcome apart from favourably influencing the time of treatment and comfort of the patient. Recent developments such as [ 64 Cu]Cu‐ATSM for imaging tumor‐hypoxia, 99 Y silicate for arthritis, 1 ⁷⁷Lu‐PSMA‐617 for prostate cancer etc has been discussed in detail in the literature. [1,2] This sectioned review deals in particular with the development of nuclear molecular theragnostic agents. The genesis and design strategies are presented after compiling recent reports.
Authors
- Shubhra Chaturvedi (ORCID: https://orcid.org/0000-0003-0285-2111)
- Ankur Kaul (ORCID: https://orcid.org/0000-0002-1935-6133)
- Deepika Sharma (ORCID: https://orcid.org/0009-0006-1119-6821)
- V. P. Singh (ORCID: https://orcid.org/0000-0002-9279-1086)
- A. K. Mishra (ORCID: https://orcid.org/0000-0001-6321-3327)
- Sunil Pal
Institutions
- Indian Institute of Technology Roorkee (IN)
- Institute of Nuclear Medicine & Allied Sciences (IN)
- Banaras Hindu University (IN)
Publication Details
- Journal
- ChemistrySelect
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/slct.202402204
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Defence Research and Development Organisation
- Banaras Hindu University
- Department of Chemistry, University of York